CY1116303T1 - Παραγωγο ακυλβενζολιου - Google Patents

Παραγωγο ακυλβενζολιου

Info

Publication number
CY1116303T1
CY1116303T1 CY20151100181T CY151100181T CY1116303T1 CY 1116303 T1 CY1116303 T1 CY 1116303T1 CY 20151100181 T CY20151100181 T CY 20151100181T CY 151100181 T CY151100181 T CY 151100181T CY 1116303 T1 CY1116303 T1 CY 1116303T1
Authority
CY
Cyprus
Prior art keywords
diabetes
acylvenzoli
producer
type
blood
Prior art date
Application number
CY20151100181T
Other languages
English (en)
Inventor
Shigeo Yamanoi
Takahiro Katagiri
Hidenori Namiki
Madoka Hatta
Koji Matsumoto
Kanako Takahashi
Tomomi Yoshitomi
Yuichi Ochiai
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of CY1116303T1 publication Critical patent/CY1116303T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Παρέχεται ένωση ή φαρμακευτικώς αποδεκτό άλας αυτής που αντιπροσωπεύεται από τον γενικό τύπο (I), που έχει εξαιρετικό αποτέλεσμα μείωσης- γλυκόζης αίματος και προστατευτικό αποτέλεσμα επί β κυττάρων ή του παγκρέατος και επίσης παρέχεται φαρμακευτική σύνθεση που έχει εξαιρετικό θεραπευτικό ή/και προφυλακτικό αποτέλεσμα έναντι σακχαρώδους διαβήτη τύπου 1, σακχαρώδους διαβήτη τύπου 2 και άλλων τέτοιων ασθενειών, όπου η γλυκόζη αίματος αυξάνει σε απόκριση προς ανωμαλίες μεταβολισμού σακχάρου.
CY20151100181T 2010-10-14 2015-02-20 Παραγωγο ακυλβενζολιου CY1116303T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010231471 2010-10-14
JP2011022325 2011-02-04
EP11832583.6A EP2628733B1 (en) 2010-10-14 2011-10-13 Acylbenzene derivative

Publications (1)

Publication Number Publication Date
CY1116303T1 true CY1116303T1 (el) 2017-02-08

Family

ID=45938375

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100181T CY1116303T1 (el) 2010-10-14 2015-02-20 Παραγωγο ακυλβενζολιου

Country Status (27)

Country Link
US (1) US8722711B2 (el)
EP (1) EP2628733B1 (el)
JP (2) JP5069813B2 (el)
KR (1) KR101829086B1 (el)
CN (1) CN103249726B (el)
AU (1) AU2011314712B2 (el)
BR (1) BR112013009043B8 (el)
CA (1) CA2814628C (el)
CO (1) CO6771403A2 (el)
CY (1) CY1116303T1 (el)
DK (1) DK2628733T3 (el)
ES (1) ES2532706T3 (el)
HK (1) HK1185082A1 (el)
HR (1) HRP20150225T1 (el)
IL (1) IL225724A (el)
MX (1) MX2013004176A (el)
MY (1) MY160300A (el)
NZ (1) NZ610145A (el)
PL (1) PL2628733T3 (el)
PT (1) PT2628733E (el)
RS (1) RS53965B1 (el)
RU (1) RU2585765C2 (el)
SG (1) SG189320A1 (el)
SI (1) SI2628733T1 (el)
SM (1) SMT201500067B (el)
TW (1) TWI487699B (el)
WO (1) WO2012050151A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140051912A (ko) * 2011-07-29 2014-05-02 다이이찌 산쿄 가부시키가이샤 Ｎ-헤테로 고리 치환 아미드 유도체
CA2861847A1 (en) 2012-01-18 2013-07-25 Daiichi Sankyo Company, Limited Substituted phenylazole derivative
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
WO2017104782A1 (ja) * 2015-12-17 2017-06-22 第一三共株式会社 オキサジアゾール化合物の製造方法
TW201731506A (zh) * 2016-01-19 2017-09-16 第一三共股份有限公司 糖尿病治療劑之倂用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4401108A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 1,2,4-Oxadiazol-Derivate
ID24564A (id) * 1997-10-06 2000-07-27 Lilly Co Eli Senyawa-senyawa baru yang berguna sebagai bahan-bahan pelindung saraf
CA2418134A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
JP4958560B2 (ja) 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
CA2613235A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
JP5114395B2 (ja) 2005-06-30 2013-01-09 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
GB0513257D0 (en) * 2005-06-30 2005-08-03 Prosidion Ltd Compounds
JPWO2007013694A1 (ja) * 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
WO2007116229A1 (en) 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic gpcr agonists
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
ES2439801T3 (es) 2009-08-05 2014-01-24 Daiichi Sankyo Company, Limited Derivado de sulfona
RU2536409C2 (ru) 2009-08-05 2014-12-20 Дайити Санкио Компани, Лимитед Амидное производное
GB201006166D0 (en) * 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
MX2013004176A (es) 2013-10-25
RU2585765C2 (ru) 2016-06-10
CA2814628C (en) 2015-06-16
JPWO2012050151A1 (ja) 2014-02-24
JP5869985B2 (ja) 2016-02-24
CN103249726B (zh) 2015-01-07
AU2011314712A1 (en) 2013-05-02
US20130217733A1 (en) 2013-08-22
HK1185082A1 (en) 2014-02-07
TWI487699B (zh) 2015-06-11
JP5069813B2 (ja) 2012-11-07
JP2012224640A (ja) 2012-11-15
RU2013121816A (ru) 2014-11-20
KR101829086B1 (ko) 2018-02-13
PT2628733E (pt) 2015-03-24
DK2628733T3 (en) 2015-03-30
BR112013009043A2 (pt) 2016-07-26
BR112013009043B1 (pt) 2019-06-18
EP2628733A1 (en) 2013-08-21
RS53965B1 (en) 2015-08-31
US8722711B2 (en) 2014-05-13
CA2814628A1 (en) 2012-04-19
MY160300A (en) 2017-02-28
NZ610145A (en) 2015-02-27
HRP20150225T1 (hr) 2015-06-19
EP2628733B1 (en) 2014-12-24
KR20130099094A (ko) 2013-09-05
CN103249726A (zh) 2013-08-14
BR112013009043B8 (pt) 2019-09-17
WO2012050151A1 (ja) 2012-04-19
AU2011314712B2 (en) 2016-05-26
PL2628733T3 (pl) 2015-05-29
CO6771403A2 (es) 2013-10-15
IL225724A (en) 2015-10-29
TW201305121A (zh) 2013-02-01
IL225724A0 (en) 2013-06-27
SMT201500067B (it) 2015-05-05
SG189320A1 (en) 2013-05-31
EP2628733A4 (en) 2014-02-26
SI2628733T1 (sl) 2015-10-30
ES2532706T3 (es) 2015-03-31

Similar Documents

Publication Publication Date Title
CY1116303T1 (el) Παραγωγο ακυλβενζολιου
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
BR112012021771A2 (pt) métodos de uso de inibidores de contransportadores de sódio-glicose 1 e 2.
CY1117183T1 (el) Διακλαδισμενα παραγωγα 3-φαινυλοπροπιονικου οξεος και η χρηση τους
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
EA201170669A1 (ru) Лечение пирфенидоном пациентов с атипичной функцией печени
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
UA107651C2 (en) Use of 5-fluorocytosine as a fungicide
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
MY169745A (en) Purinone derivative
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
BR112014003704A2 (pt) moduladores ror gama
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
WO2015089360A8 (en) Inhibitors of mitochondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof
EA201071209A1 (ru) Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови
PH12014501646A1 (en) Substituted phenylazole derivative
NZ630385A (en) Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance
MX2012001107A (es) Derivado de amida.
TW200640842A (en) Derivatives of aminobutanoic acid inhibiting CPT